+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Mullerian Hormone Test Market by Test Type (Chemiluminescence Immunoassay, ELISA Test Kits, Rapid Point-of-Care Test Kits), Sample Type (Blood Samples, Saliva Samples), End-user, Test Purpose, Technology, Application - Global Forecast 2025-2030- Product Image
Anti-Mullerian Hormone Test Market by Test Type (Chemiluminescence Immunoassay, ELISA Test Kits, Rapid Point-of-Care Test Kits), Sample Type (Blood Samples, Saliva Samples), End-user, Test Purpose, Technology, Application - Global Forecast 2025-2030- Product Image
Sale

Anti-Mullerian Hormone Test Market by Test Type (Chemiluminescence Immunoassay, ELISA Test Kits, Rapid Point-of-Care Test Kits), Sample Type (Blood Samples, Saliva Samples), End-user, Test Purpose, Technology, Application - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 185 Pages
  • November 2024
  • Region: Global
  • 360iResearch™
  • ID: 5292895
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anti-Mullerian Hormone Test Market grew from USD 274.26 million in 2023 to USD 305.41 million in 2024. It is expected to continue growing at a CAGR of 11.46%, reaching USD 586.48 million by 2030.

The Anti-Mullerian Hormone (AMH) Test serves as a crucial tool in assessing ovarian reserve and fertility potential, primarily used in fertility clinics, hospitals, and research settings. This test measures levels of AMH in the blood, which provide insights into a woman's remaining egg supply and can assist in diagnosing and treating conditions like polycystic ovary syndrome (PCOS) and premature ovarian failure. The necessity of AMH testing is driven by rising infertility rates, delayed family planning, and increasing awareness of fertility preservation. It finds application in tailoring individualized reproductive treatments, predicting menopause onset, and evaluating ovarian response for IVF procedures.

End-users mainly include women considering fertility treatment, medical professionals in reproductive health, and research institutions. The market's growth is influenced by an increase in the global fertility rate, advancements in diagnostic technology, and heightened awareness about fertility health. Emerging opportunities stem from the integration of AMH tests into personalized medicine and fertility treatment strategies, promising enhanced reproductive outcomes. Market expansion is further bolstered by the digitization of healthcare records which facilitates improved test management and data analysis.

However, market growth faces limitations from the high cost of tests, variability in AMH levels due to demographic factors, and a lack of uniform testing protocols globally. Challenges also include ethical concerns surrounding fertility treatments and limited access to advanced healthcare facilities in underdeveloped regions. Innovation areas include developing more accurate and less invasive testing methods, combining AMH testing with other biomarkers for comprehensive fertility assessment, and leveraging AI for predictive fertility analytics. The AMH Test market, characterized by competition among diagnostic companies and healthcare technology firms, presents robust potential for growth, particularly in regions witnessing rising fertility treatment demand and advancing healthcare infrastructure.

Understanding Market Dynamics in the Anti-Mullerian Hormone Test Market

The Anti-Mullerian Hormone Test Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Progressive healthcare infrastructure and a rise in personalized medicine approaches boosting adoption.
    • Increasing awareness and education about fertility and reproductive health among the global population
    • Evolving societal norms and changing family structures promoting proactive fertility management
  • Market Restraints
    • High operational costs and limited reimbursement policies constrain the anti-mullerian hormone test market
    • Numerous challenges in the market impede the widespread adoption of anti-mullerian hormone tests
    • Despite its potential, the anti-mullerian hormone test market is restrained by various factors
  • Market Opportunities
    • Collaborating with insurance providers to cover AMH tests under health policies to broaden customer base
    • Promoting AMH testing as an essential tool for personalized medicine within the broader fertility landscape
    • Enhancing digital platforms for seamless AMH test booking and result management to improve user experience
  • Market Challenges
    • Anticipating slow adoption rates due to lack of awareness and understanding among potential users
    • Navigating the high costs of anti-mullerian hormone tests in a competitive healthcare market
    • Identifying and targeting the appropriate consumer segments for effective market penetration

Exploring Porter’s Five Forces for the Anti-Mullerian Hormone Test Market

Porter’s Five Forces framework further strengthens the insights of the Anti-Mullerian Hormone Test Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Anti-Mullerian Hormone Test Market

External macro-environmental factors deeply influence the performance of the Anti-Mullerian Hormone Test Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Anti-Mullerian Hormone Test Market

The Anti-Mullerian Hormone Test Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Anti-Mullerian Hormone Test Market

The Anti-Mullerian Hormone Test Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Anti-Mullerian Hormone Test Market

The Anti-Mullerian Hormone Test Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Mullerian Hormone Test Market, highlighting leading vendors and their innovative profiles. These include Abbexa Limited, Abcam PLC, Ansh Labs LLC, Athenese-Dx, Beckman Coulter, Inc. by Danaher Corporation, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, bioMérieux S.A., BioVendor - Laboratorni Medicina A.S., Chengdu VACURE Biotechnology Co., Ltd., CTK Biotech, Inc., Cusabio Technology LLC, Eagle Biosciences, Inc., Elabscience Bionovation Inc., Epitope Diagnostics, Inc., F.

Hoffmann-La Roche Ltd., Fujirebio Europe N.V. by H.U. Group Holdings, Inc., Goldsite Diagnostics Inc., Healthy Human Labs Limited (Vitall), Kamiya Biomedical Company, LifeSpan BioSciences, Inc., London Gynaecology Limited, Meridian Bioscience, Inc., Monobind Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Tosoh Corporation, and Vitrosens Biotechnology Co., Ltd.

Market Segmentation & Coverage

This research report categorizes the Anti-Mullerian Hormone Test Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Test Type
    • Chemiluminescence Immunoassay
      • High Throughput Systems
      • Low Throughput Systems
    • ELISA Test Kits
      • Automated ELISA Kits
      • Manual ELISA Kits
    • Rapid Point-of-Care Test Kits
      • Clinic-Based Test Kits
      • Home-Based Test Kits
  • Sample Type
    • Blood Samples
      • Plasma Samples
      • Serum Samples
    • Saliva Samples
  • End User
    • Diagnostic Laboratories
      • Hospital-Based Laboratories
      • Independent Laboratories
    • Fertility Clinics
    • Hospitals
      • Private Hospitals
      • Public Hospitals
    • Research Institutes
      • Academic Institutes
      • Clinical Research Organizations
  • Test Purpose
    • Cancer Treatment Monitoring
      • Breast Cancer
      • Ovarian Cancer
    • Fertility Assessment
      • Baseline Fertility Testing
      • Monitoring Ovarian Reserve
    • Menopause Onset Prediction
    • Polycystic Ovary Syndrome Diagnosis
  • Technology
    • Immunoassay Technology
    • Microarray Technology
    • Polymerase Chain Reaction
  • Application
    • Benchmarking Ovarian Age
    • Clinical Testing
    • Menstruation Disorders
      • Amenorrhea
      • Irregular Menstrual Cycles
    • Research And Development
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States (California, Florida, Illinois, New York, Ohio, Pennsylvania, Texas)
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  • Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  • Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  • Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  • Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  • Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  • What is the current size of the market, and how is it expected to grow?
  • Which products, segments, and regions present the most attractive investment opportunities?
  • What are the prevailing technology trends and regulatory factors influencing the market?
  • How do top vendors rank regarding market share and competitive positioning?
  • What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Progressive healthcare infrastructure and a rise in personalized medicine approaches boosting adoption.
5.1.1.2. Increasing awareness and education about fertility and reproductive health among the global population
5.1.1.3. Evolving societal norms and changing family structures promoting proactive fertility management
5.1.2. Restraints
5.1.2.1. High operational costs and limited reimbursement policies constrain the anti-mullerian hormone test market
5.1.2.2. Numerous challenges in the market impede the widespread adoption of anti-mullerian hormone tests
5.1.2.3. Despite its potential, the anti-mullerian hormone test market is restrained by various factors
5.1.3. Opportunities
5.1.3.1. Collaborating with insurance providers to cover AMH tests under health policies to broaden customer base
5.1.3.2. Promoting AMH testing as an essential tool for personalized medicine within the broader fertility landscape
5.1.3.3. Enhancing digital platforms for seamless AMH test booking and result management to improve user experience
5.1.4. Challenges
5.1.4.1. Anticipating slow adoption rates due to lack of awareness and understanding among potential users
5.1.4.2. Navigating the high costs of anti-mullerian hormone tests in a competitive healthcare market
5.1.4.3. Identifying and targeting the appropriate consumer segments for effective market penetration
5.2. Market Segmentation Analysis
5.2.1. Product: Increasing consumer preference for POC testing to obtain professional oversight
5.2.2. End-User: Rising penetration of AMH test kits in commercial labs for accurate and rapid results
5.2.3. Distribution: Emerging availability of AMH testing kits on online channels
5.2.4. Use: Significant usage of AMH testing kits for human applications
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Anti-Mullerian Hormone Test Market, by Test Type
6.1. Introduction
6.2. Chemiluminescence Immunoassay
6.2.1. High Throughput Systems
6.2.2. Low Throughput Systems
6.3. ELISA Test Kits
6.3.1. Automated ELISA Kits
6.3.2. Manual ELISA Kits
6.4. Rapid Point-of-Care Test Kits
6.4.1. Clinic-Based Test Kits
6.4.2. Home-Based Test Kits
7. Anti-Mullerian Hormone Test Market, by Sample Type
7.1. Introduction
7.2. Blood Samples
7.2.1. Plasma Samples
7.2.2. Serum Samples
7.3. Saliva Samples
8. Anti-Mullerian Hormone Test Market, by End User
8.1. Introduction
8.2. Diagnostic Laboratories
8.2.1. Hospital-Based Laboratories
8.2.2. Independent Laboratories
8.3. Fertility Clinics
8.4. Hospitals
8.4.1. Private Hospitals
8.4.2. Public Hospitals
8.5. Research Institutes
8.5.1. Academic Institutes
8.5.2. Clinical Research Organizations
9. Anti-Mullerian Hormone Test Market, by Test Purpose
9.1. Introduction
9.2. Cancer Treatment Monitoring
9.2.1. Breast Cancer
9.2.2. Ovarian Cancer
9.3. Fertility Assessment
9.3.1. Baseline Fertility Testing
9.3.2. Monitoring Ovarian Reserve
9.4. Menopause Onset Prediction
9.5. Polycystic Ovary Syndrome Diagnosis
10. Anti-Mullerian Hormone Test Market, by Technology
10.1. Introduction
10.2. Immunoassay Technology
10.3. Microarray Technology
10.4. Polymerase Chain Reaction
11. Anti-Mullerian Hormone Test Market, by Application
11.1. Introduction
11.2. Benchmarking Ovarian Age
11.3. Clinical Testing
11.4. Menstruation Disorders
11.4.1. Amenorrhea
11.4.2. Irregular Menstrual Cycles
11.5. Research And Development
12. Americas Anti-Mullerian Hormone Test Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Anti-Mullerian Hormone Test Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Anti-Mullerian Hormone Test Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.3.1. Introduction of Novel Assay by Siemens Healthineers' for Assessing Ovarian Reserve
15.3.2. The Introduction of MenoCheck by ARUP Laboratories to Revolutionizing Menopausal Management
15.3.3. The Advent of the Elecsys Anti-Müllerian Hormone Plus immunoassay for Enhanced Accessibility and Early Detection
15.3.4. Innovative At-Home Fertility Test by Fertilly for Understanding Reproductive Health through Anti-Müllerian Hormone Analysis
15.3.5. Strategic Acquisition of Meridian Bioscience by SD Biosensor and SJL Partners for Enhanced Growth and Global Impact
15.3.6. Randox Quality Control Introduces Advanced Acusera AMH Control for Enhanced Reproductive Testing
15.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ANTI-MULLERIAN HORMONE TEST MARKET MULTI-CURRENCY
FIGURE 2. ANTI-MULLERIAN HORMONE TEST MARKET MULTI-LANGUAGE
FIGURE 3. ANTI-MULLERIAN HORMONE TEST MARKET RESEARCH PROCESS
FIGURE 4. ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2023 VS 2030
FIGURE 5. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 17. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 19. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 23. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. ANTI-MULLERIAN HORMONE TEST MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 29. ANTI-MULLERIAN HORMONE TEST MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTI-MULLERIAN HORMONE TEST MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ANTI-MULLERIAN HORMONE TEST MARKET DYNAMICS
TABLE 7. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HIGH THROUGHPUT SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY LOW THROUGHPUT SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY AUTOMATED ELISA KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MANUAL ELISA KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CLINIC-BASED TEST KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOME-BASED TEST KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PLASMA SAMPLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SERUM SAMPLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SALIVA SAMPLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITAL-BASED LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BASELINE FERTILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MONITORING OVARIAN RESERVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENOPAUSE ONSET PREDICTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY IMMUNOASSAY TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BENCHMARKING OVARIAN AGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CLINICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY AMENORRHEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY IRREGULAR MENSTRUAL CYCLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 112. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 113. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 114. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 115. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 116. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 117. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 118. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 120. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 121. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 122. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 123. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 124. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 125. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. CANADA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 128. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 129. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 130. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 131. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 132. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 133. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 134. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 136. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 137. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 138. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 139. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 140. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 141. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. MEXICO ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 194. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 195. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 196. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 197. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 198. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 199. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 200. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 202. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 203. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 204. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 205. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 206. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 207. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 208. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. CHINA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 210. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 211. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 212. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 213. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 214. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 215. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 216. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 218. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 219. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 220. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 221. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 222. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 223. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 224. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. INDIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 229. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 230. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 231. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 232. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 234. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 237. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 238. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 241. INDONESIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 242. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 243. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 244. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 245. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 246. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 247. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 248. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 249. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 250. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 251. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 252. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 253. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 254. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 255. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 256. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 257. JAPAN ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 266. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 267. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 268. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 269. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 270. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 271. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 272. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. MALAYSIA ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 274. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 275. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 276. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 277. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 278. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 279. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 280. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 282. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 283. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 284. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 285. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 286. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 287. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 290. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 291. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 292. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY ELISA TEST KITS, 2018-2030 (USD MILLION)
TABLE 293. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RAPID POINT-OF-CARE TEST KITS, 2018-2030 (USD MILLION)
TABLE 294. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 295. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY BLOOD SAMPLES, 2018-2030 (USD MILLION)
TABLE 296. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 298. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 299. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 300. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TEST PURPOSE, 2018-2030 (USD MILLION)
TABLE 301. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY CANCER TREATMENT MONITORING, 2018-2030 (USD MILLION)
TABLE 302. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY FERTILITY ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 303. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE ANTI-MULLERIAN HORMONE TEST MARKET SIZE, BY MENSTRUATION DISORDERS, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA ANTI-MULLERI

Companies Mentioned

  • Abbexa Limited
  • Abcam PLC
  • Ansh Labs LLC
  • Athenese-Dx
  • Beckman Coulter, Inc. by Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • bioMérieux S.A.
  • BioVendor – Laboratorni Medicina A.S.
  • Chengdu VACURE Biotechnology Co., Ltd.
  • CTK Biotech, Inc.
  • Cusabio Technology LLC
  • Eagle Biosciences, Inc.
  • Elabscience Bionovation Inc.
  • Epitope Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fujirebio Europe N.V. by H.U. Group Holdings, Inc.
  • Goldsite Diagnostics Inc.
  • Healthy Human Labs Limited (Vitall)
  • Kamiya Biomedical Company
  • LifeSpan BioSciences, Inc.
  • London Gynaecology Limited
  • Meridian Bioscience, Inc.
  • Monobind Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Tosoh Corporation
  • Vitrosens Biotechnology Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages185
PublishedNovember 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 305.41 million
Forecasted Market Value ( USD ) by 2030 $ 586.48 million
Compound Annual Growth Rate11.4%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Anti-Mullerian Hormone Test Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Anti-Mullerian Hormone Test Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Endocrine Testing Market Size, Share & Trends Analysis Report by Test Type (TSH, hCG Hormone), End-use (Hospitals, Commercial Laboratories), Technology (Immunoassay, Clinical Chemistry), and Segment Forecasts, 2024-2030 - Product Image

Endocrine Testing Market Size, Share & Trends Analysis Report by Test Type (TSH, hCG Hormone), End-use (Hospitals, Commercial Laboratories), Technology (Immunoassay, Clinical Chemistry), and Segment Forecasts, 2024-2030

  • Report
  • 180 Pages
  • Global
From
Automated Immunoassay Analyzers - Global Strategic Business Report - Product Image

Automated Immunoassay Analyzers - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Immunoassay Market by Product, Technology, Specimen, Indication, End User - Global Forecast 2025-2030 - Product Image

Immunoassay Market by Product, Technology, Specimen, Indication, End User - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Immunoassay Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032) - Product Image

Immunoassay Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

  • Report
  • 154 Pages
  • Global
From

About the Anti Mullerian Hormone Test Market

The Anti Mullerian Hormone (AMH) Test is a diagnostic tool used to measure the amount of AMH in a person's blood. AMH is a hormone produced by the ovaries and is used to assess ovarian reserve, or the number of eggs a woman has left in her ovaries. The test is used to help diagnose infertility, polycystic ovary syndrome, and other conditions related to the reproductive system. It is also used to monitor the effectiveness of fertility treatments. The AMH Test market is a growing segment of the diagnostics industry. It is used by fertility clinics, obstetricians, and gynecologists to help diagnose and treat reproductive issues. The test is also used in research studies to better understand the reproductive system. Some companies in the AMH Test market include Beckman Coulter, Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.